Navigation Links
Kinexus Announces the Launch of a New Protein Kinase Microarray
Date:2/10/2010

New kinase array designed for drug screening, substrate profiling and kinase interaction discovery

VANCOUVER, Feb. 10 /PRNewswire/ - Kinexus Bioinformatics Corporation announced the commercial release of its novel Protein Kinase Microarray with 200 recombinant human protein kinases for screening. The microarray has wide utility including applications for drug target counter screening, to identify novel kinase substrates, establish kinase antibody specificities, and for the discovery and testing of protein kinase-protein and protein kinase-compound interactions.

With these new and unique kinase microarray services, clients can now inexpensively assay the abilities of their lead compounds to inhibit any of the 200 different protein kinases for as low as $1.65 per kinase with triplicate measurements. Industry standards for these types of measurements typically cost $4-5 per kinase tracked. This counter screening of kinases can be used to establish the specificity of promising therapeutic inhibitors or target kinases in much more cost effective manner than previously available. All compounds can be further validated for direct activity effects in vitro with the Kinase-Inhibitor Profiling Services offered by Kinexus. This complements the Kinex(TM) 800 Antibody Microarray Services, in which endogenous physiological substrates of target kinases can also be defined to measure the effects of drug leads in vivo in cultured cells and tissues from treated animals. The specificity of suspected protein kinase-protein interactions can also be investigated with the new kinase microarray.

"Protein kinases are well recognized by the pharmaceutical and biotech industry as highly productive targets for drugs with the potentially treat over 400 human diseases, commented Dr. Steven Pelech, President and Chief Scientific Officer of Kinexus. "With 516 human protein kinases and only about 75 that have been seriously targeted by the pharmaceutical industry so far, there are exciting possibilities for the identification of new kinase drug targets and new applications for existing drugs with this type of technology".

To learn more about the Protein Kinase Microarray Service or any of the other proteomics services available, please visit www.kinexus.ca. Kinexus is a private, biotechnology company engaged in the research and development of innovative methods to map the relationships of signalling proteins in cellular communication networks. The application of this knowledge positions Kinexus and its clients in drug development, rational drug design, disease diagnosis and personalized therapies to improve human health.

SOURCE Kinexus Bioinformatics Corporation


'/>"/>
SOURCE Kinexus Bioinformatics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
2. Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results
3. Silicon Kinetics Announces New Biosensor Chips With Wide Palette of Surface Chemistries
4. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
5. Healthcare Data Solutions Announces Expansion of its Healthcare Customer Solutions Team With Two Key Additions
6. Angiotech Pharmaceuticals Announces Conference Call and Webcast
7. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
8. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
9. Telik Announces Presentation and Webcast at 12th Annual BIO CEO & Investor Conference
10. Zimmer Holdings Announces 2010 Funding for OMeGA Medical Grants Association
11. Dalton Pharma Services Announces Successful Completion of Health Canada Inspection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... maternal age to IVF success. , After comparing the results from the fresh ...
(Date:10/10/2017)... ... 10, 2017 , ... For the second time in three ... Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October ... US2020’s mission is to change the trajectory of STEM education in America by ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... and business process optimization firm for the life sciences and healthcare industries, announces ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud ...
(Date:10/9/2017)... ... , ... At its national board meeting in North Carolina, ARCS® Foundation ... of Physics and Astronomy, has been selected for membership in ARCS Alumni Hall ... 2015 Breakthrough Prize in Fundamental physics for the discovery of the accelerating expansion of ...
Breaking Biology Technology:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
Breaking Biology News(10 mins):